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Before being able to react against infectious non-self-antigens, the immune system has to be educated in the recognition and
tolerance of neuroendocrine proteins, and this critical process essentially takes place in the thymus. The development of the
autoimmunediabetogenicresponseresultsfromathymusdysfunctioninprogrammingcentralself-tolerancetopancreaticinsulin-
secreting islet β cells, leading to the breakdown of immune homeostasis with an enrichment of islet β cell reactive eﬀector T cells
and a deﬁciency of β cell-speciﬁc natural regulatory T cells (nTreg) in the peripheral T-lymphocyte repertoire. Insulin-likegrowth
factor 2 (IGF-2) is the dominant member of the insulin family expressed during fetal life by the thymic epithelium under the
control of the autoimmune regulator (AIRE) gene/protein. Based on the close homology and cross-tolerance between insulin,
the primary T1D autoantigen, and IGF-2, the dominant self-antigen of the insulin family, a novel type of vaccination, so-called
“negative/tolerogenic self-vaccination”, is currently developed for prevention and cure of T1D. If this approach were found to be
eﬀective for reprogramming immunologicaltolerance in T1D, it could pave the wayfor the design of negative self-vaccines against
autoimmuneendocrine diseases, as well as other organ-speciﬁc autoimmune diseases.
1.Introduction
Type 1 diabetes (T1D) is a chronic autoimmune disorder as-
sociated, in genetically susceptible individuals, with the gen-
eration and activation of autoreactive T cells recognizing
pancreaticβcellautoantigens.AutoreactiveCD4+andCD8+
T cells inﬁltrate pancreatic Langerhans’ islets (insulitis) and
selectively destroy the insulin-producing β cells in these
structures. This destruction occurs silently and progressively
and, in most cases, remains undetected for many years. By
the time the ﬁrst clinical T1D symptoms become apparent,
nearly 80% of the patients’ β cells have been destroyed and
t h e r ei sl i t t l eh o p ef o rc u r i n gt h ed i s e a s e .I nh u m a n s ,T 1 D
incidence peaks around 10–14 years of age. It is estimated
thatT1Daﬀectsabout30millionpeopleworldwide (approx-
imately 10–15% of all patients with diabetes mellitus).
MajorT1Dautoantigensinclude(pro)insulin,the65-kDa
isoform of glutamic acid decarboxylase (GAD65), the islet
tyrosine phosphatase IA-2, and the islet-speciﬁc glucose-6-
phosphatase catalytic subunit-related protein (IGRP). These
pancreatic β-target autoantigens have been identiﬁed in
both humans and nonobese diabetic (NOD) mice [1]. The
generation ofautoreactivity to islet β cells is the consequence
of multiple various genetic defects that have an impact
on fundamental immunological processes such as central
and peripheral tolerance. In general, potentially autoreactive
lymphocytes must encounter their cognate autoantigen dur-
ing diﬀerentiation in order for the host to develop tolerance
toself-antigens.Thisencountermayoccurwithinthethymus
or upon release into the periphery [2, 3]. Central self-
tolerance occurs during T-cell diﬀerentiation in the thymus
and involves deletion (negative selection) of self-reactive T
cells during T-cell development in the thymus [4]. This
process occurs to eliminate T cells that recognize ubiquitous
or blood-borne self-antigens. T cells which recognize tissue-
speciﬁc antigens (TSAs), however, were long-thought to be2 Clinical and Developmental Immunology
tolerized in the periphery [3]. Until recently, it was widely
assumed that such TSAs are excluded from the thymus,
precluding central self-tolerance. To explain tolerance to
TSAs,numerous peripheral tolerancemechanisms havebeen
suggested, including ignorance and immunoregulation. At
thesametimeithasalsobeenarguedthatTSAsmayreachthe
thymus in signiﬁcant quantities and thereby induce negative
selection in situ, especially of high-aﬃnity T cells. This idea
became more plausible when others and we found that many
TSAs are expressed by rare medullary thymic epithelial cells
(mTEC) [5–7]. Findings such as these challenged historical
assumptions about tolerance to TSAs and intense investiga-
tions, in both mice and humans, have elucidated the identity
of TSA-expressing cells in the thymus, as well as their role in
the process of central self-tolerance. Others and we showed
that genetically determined low levels of TSAs (i.e., insulin)
expression in the thymus is associated with the generation of
high numbers of autoreactive T cells in the periphery and
predisposition to autoimmune disease [5–7]. The ectopic
expression of many tissue-restricted antigens in the thymus
is controlled by the autoimmune regulator (AIRE). AIRE is
a 54.5-kDa protein with a nuclear localization and several
potential DNA-binding and protein interaction domains
[8]. AIRE−/− mice exhibit a deﬁned proﬁle of autoimmune
diseases including T1D. It is notable that all these diseases
arise due to a lack of AIRE expression in stromal cells of
the thymus. Furthermore, AIRE-deﬁcient mTEC showed a
speciﬁc reduction in promiscuous transcription of genes
encodingperipheralantigens,demonstratingtheimportance
ofthymus-dependenttolerancein controlling autoimmunity
[9].
Althoughthesedataare appealing, theydonotprovethat
thymicexpressionofTSAsautomaticallyinducescentralself-
tolerance to peripheral tissues. Other potential mechanisms
for developingtolerance to TSAsalso includethymic genera-
tion of self-antigen-speciﬁc Foxp3+CD4+CD25+ regulatory
T cells or Treg (“dominant” central self-tolerance). In the
last 25 years, Foxp3+CD4+CD25+ Treg have been identiﬁed
as key eﬀectors in the maintenance of peripheral tolerance.
It has also been shown that the promiscuous expression
of a neo-self-antigen in TEC may be involved in the
selective induction and/or expansion of self-antigen-speciﬁc
Foxp3+CD4+CD25+ Treg thymic precursors as early as the
double-positivestage [10]. Importantly, thisselection ofself-
antigen-speciﬁc Foxp3+ Treg is mediated by AIRE+m T E C
[11]. In this paper, we highlight the recent progress in the
ﬁeld of central and peripheral self-tolerance exempliﬁed by
T1D pathogenesis as consequence of a deleterious process in
T-cell tolerance installment.
2.T1D-AssociatedAutoantigensand
Autoimmunity
Animportant steptodemonstratetheautoimmunenatureof
T1D was the discovery of autoantibodies directed against
Langerhans’ islet cells [12]. Major autoantigens include
(pro)insulin itself, GAD65 and IGRP. The islet-speciﬁc
cation eﬄux transporter ZnT8 (Slc30A8)and chromogranin
Ahavebeenalso recentlyreportedasimportant autoantigens
in T1D [13, 14]. However, among these autoantigens, only
antigenic epitopes derived from (pro)insulin are speciﬁc
of pancreatic islet β cells. Furthermore, there is now
ample evidence that autoimmunity to (pro)insulin is central
to autoimmune diabetes pathogenesis both in non-obese
diabetic (NOD) mice and in humans [15, 16]. Clinically,
detection of anti-insulin, anti-GAD65, and/or anti-IA-2
autoantibodies are very reliable markers of the autoimmune
response targeting β cells. The majority of the children
with recent-onset of T1D (more than 90%) have antibodies
against one or several of these autoantigens in their serum.
Their high predictive value is also established since they can
be detected several years before the clinical signs of insulin
deﬁciency. The predictive value of autoantibodies against
several autoantigens is higher than elevated titers of one sin-
gle autoantibody. The combination of autoantibodies with
susceptible genetic alleles of the major histocompatibility
(MHC) class II locus further increases this predictive value.
Such prediction is very useful for clinical studies targeted
at T1D prevention given the relatively low incidence of this
disease [17, 18]. However, the pathogenic signiﬁcance of
T1D-related autoantibodies is rather low, if not absent [19],
and the principal eﬀectors of β cell autoimmune destruction
are CD4+ and CD8+ T lymphocytes [20]. Investigation of
speciﬁc T-cell responses in T1D patients is however chal-
lenging because of the very low frequency in the peripheral
T-cell pool of autoreactive T cells speciﬁc for epitopes
derived from (pro)insulin, GAD65, or IA-2. However, the
development of sensitive and speciﬁc techniques, such as
enzyme-linked immunosorbant spot assays (ELISpot) and
multimers of class I/II HLA molecules complexed with T1D-
related epitopes, has already provided very signiﬁcant data
that further document the importance of T-cell-mediated
mechanisms in T1D pathogenesis [21, 22].
3.Th eCen tralR oleofth eTh ym usinCen tral
Self-Toleranceof NeuroendocrineProteins
and the Nature of“NeuroendocrineSelf”
A major question when addressing the pathogenesis of or-
gan-speciﬁc autoimmunity such as T1D is the origin of the
self-reactive T cellsthatare directedagainst targetantigensof
endocrine cells. Among all lymphoid structures, the thymus
is an organ that emerged some 500 million years ago,
concomitantly or very shortly after recombinase-dependent
adaptive immunity, with a speciﬁc function in orchestrating
central immunological self-tolerance. The thymus is not an
endocrine gland, but it crucially stands at the intersection
between the immune and neuroendocrine systems. In this
organ thatisresponsible forthymopoiesis, thatis, generation
of na¨ ıve and competent T lymphocytes, the neuroendocrine
system regulates the process of T-cell diﬀerentiation from
very early stages, while in parallel na¨ ıve T lymphocytes are
educatedtorecognizeandtolerateneuroendocrinegene/pro-
tein families [7, 23, 24]. Contrary to the popular opinion,
the thymus continues to function throughout life and plays
a fundamental role in the recovery of a competent T-cellClinical and Developmental Immunology 3
repertoire after intensive chemotherapy or during highly
active antiretroviral chemotherapy in human immunodeﬁ-
ciency virus infection [25, 26]. The integrity of the somato-
trope growth hormone/IGF-1 axis is known to be important
for the maintenance of thymus function in adult life [27].
Thethymus isthecentrallymphoidorgan responsiblefor
the maturation and diﬀerentiation of bone-marrow-derived
thymocytes. The random generation of the T-cell repertoire,
including autoreactive T cells, is regulated in the thymus
by mechanisms of central self-tolerance. Anatomically, the
thymus is divided into subcapsular, cortical, and medullary
compartments. The stromal cells include a variety of bone-
marrow-derived professional antigen-presenting cells (den-
dritic cells [DC], macrophages, and B cells) and endoderm-
derived cortical (c) TEC and mTEC [28]. A striking mor-
phologic feature of the medulla is the presence of Hassall’s
corpuscles, which consist of concentric whorls of stratiﬁed
keratinizing epithelium and share antigenic properties with
ectodermic epithelium [29]. The thymus constitutes the
central arm of immunological self-tolerance by two essential
mechanisms that are intimately associated and paradoxically
mediated by the same thymic self-antigens: (a) negative
selection of self-reactive T cells issued from the random
recombination of TCR genes (“recessive” self-tolerance) and
(b) generation of self-antigen-speciﬁc nTreg that are able to
inactivate in periphery self-reactive T cells having escaped
intrathymic negative selection (“dominant” self-tolerance)
[30, 31].
Several groups and ourselves have demonstrated that
TECfrom diﬀerentspecies constitutea site forthepromiscu-
oustranscription ofagreatnumberofgenesencodingtissue-
restricted antigens or belonging to neuroendocrine families,
suchas theneurohypophysialfamily, tachykinins, neurotens-
ins, somatostatins, atrial natriuretic peptides, and the insulin
family. This demonstration has radically changed our com-
mon understanding of the pathogenesis of organ-speciﬁc
autoimmune endocrine diseases such as T1D. From the
investigation of intrathymic expression of neuroendocrine-
related self-peptide precursor genes, a series of properties
can be derived that deﬁne the nature of the “neuroendocrine
self”. First, thymic neuroendocrine self-antigens usually
correspond to peptide sequences that have been highly
conserved throughout the evolution of their related family.
Second, a hierarchy characterizes their expression pattern in
the thymus. In the neurohypophysial family, oxytocin (OT)
is the dominant peptide synthesized by TEC from diﬀerent
species. The binding of OT to its cognate receptor expressed
by pre-T cells induces a very rapid phosphorylation of focal
adhesion-related kinases. This event could play a major role
in promoting establishment of synapses between immature
T lymphocytes and TEC, as well as with macrophages and
DC. All the genes of the insulin family are expressed in
the thymus according to a precise hierarchy during fetal
life: IGF2 (cTEC and mTEC) >IGF1>INS (a few subsets
of mTEC). This hierarchical pattern is meaningful because
the strength of self-tolerance to a protein is proportional to
its intrathymic concentration [32]. Third, neuroendocrine
precursors are not processed according to the classic model
of neurosecretion, but they undergo an antigenic processing
for presentation by—or in association with—MHC proteins
[33]. Fourth, most of neuroendocrine self-antigens are
transcribed in the thymic epithelium under the control of
the autoimmune regulator gene AIRE (see below). Fifth,
intrathymic OT transcription precedes OT and vasopressin
(VP) expression in hypothalamic magnocellular neurons.
Finally, epigenetic regulation of intrathymic gene expression
is strongly suggested by the loss of IGF2 parental imprinting
in human mTEC [34, 35].
This hierarchy in the organization of the thymic reper-
toire of neuroendocrine self-antigens is also signiﬁcant from
an evolutionary point of view. Since a series of essential
and physiological functions had been established before the
appearance of adaptive immunity in cartilaginous ﬁshes,
they had to be protected from the risk of autotoxicity inher-
ent tothistype ofimmunity. Forexample, OT is a“bonding”
peptide that has been implicated at diﬀerent steps of the
reproductive process and thus, for species preservation, OT
possibly had to be protected to a greater degree than VP,
which controls water metabolism and vascular tone. Along
the same line of reasoning, IGF-2 as a major factor in fetal
developmentpossibly had to be more protected than insulin,
which “only” regulates glucose homeostasis. Nevertheless,
because of their close homology, thymic neuroendocrine
self-antigens may promotecross-tolerance to othermembers
of their respective families. This is supported by the weaker
tolerance to insulin of Igf2−/− mice when compared to wild-
type mice [36]. Further insight into the relative inﬂuence
of the central arm of immunological self-tolerance will
be gained through the generation of mice with TEC-
speciﬁc Igf2 deletion, currently under development in our
laboratory.
4.TheCentralRoleofaThymusDysfunctionin
T1DPathogenesis(Figure1)
As hypothesized by Burnet in 1973, the pathogenesis of
autoimmune diseases may ﬁrst depend on the appearance
of “forbidden” self-reactive clones in the peripheral T-cell
repertoire [37].In1992,adefectintheprocessofintrathymic
T-cell education to recognize and to tolerate OT was
hypothesized to play a pivotal role in the development
of hypothalamus-speciﬁc autoimmunity leading to “idio-
pathic” central diabetes insipidus [38]. The progressive
increase in the degree of immune diversity and complexity
may explain why failures in self-tolerance are increasingly
detected during evolution with most such failures occurring
in the human species. Since the thymus is the primary site
for induction of self-tolerance, a thorough investigation of
the mechanisms responsible for a breakdown of thymus-
dependent tolerance should provide the scientiﬁc commu-
nity with important keys to understand the mechanisms
underlying the developmentof autoimmune responses.
A number of abnormalities of thymic morphology
and cytoarchitecture have been described in T1D. Central
tolerance and apoptosis of self-reactive T cells are defective
in the thymus of NOD mouse [39, 40]. Transcription of
insulin-related genes(Ins, Igf1,andIgf2)hasbeenanalyzedin4 Clinical and Developmental Immunology
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Intrathymic AIRE-mediated transcription of T1D-related genes
Deletion of T cells expressing a TCR with high aﬃnity for T1D-related self-epitopes
Selection of CD4+CD25+Foxp3+ nTreg, speciﬁc of T1D-related self-epitopes
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(APECED/APS-I, Aire
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(IGF2 > IGF1 > INS; GAG67 > GAD65)
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Thymus physiology
Thymus physiopathology
Bridge between autoreactive Teﬀandtarget β-cellautoantigens
Role of environmental factors (viruses, diet, vitamin D defciency, stress...).
Figure 1: Thymus physiopathology and T1D development. Throughout life, the thymus selects self-tolerant and competent T cells against
non-self-antigens and generates self-speciﬁc nTreg. Under control by AIRE for most of them, thymic epithelium transcribes genes encoding
T1D-related antigens, as well as other neuroendocrine-related and tissue-restricted antigens. Absence or decrease in presentation of thymic
T1D-related antigens (as observed in diﬀerent animal models of autoimmune diabetes) conducts to the enrichment of the peripheral T-cell
pool with “forbidden” self-reactive T cells (Teﬀ) bearing a TCR directed against T1D-related epitopes, while thymic generation of speciﬁc
nTreg is severely impaired. Combination of these two events is responsible for the breakdown of central self-tolerance to islet β cells. Both
genetic and environmental factors are involved in the establishment of a molecular bridge between anti-β cell self-reactive Teﬀ and islet β
cell autoantigens. Once this bridge is formed, the autoimmunepathogenic response is triggered and leads to a progressive destruction of the
β cell mass.
the thymus of diabetes-resistant (BBDR) and diabetes-prone
(BBDP) rats, another model of T1D. Ins and Igf1 transcripts
were detected in all thymi from BBDP and BBDR rats. Igf2
transcripts were also present in the thymus from all BBDR
rats, but were not detected in the thymus from more than
80% of BBDP rats, in close concordance with the incidence
(86%) of autoimmune diabetes in those rats. This defect in
Igf2 transcription in BBDP thymus could also explain both
their lymphopenia (including CD8+ T cells and RT6+ Treg)
and the absence of central self-tolerance to insulin-secreting
islet β cells [41, 42]. As already mentioned, we have shown
that susceptibility to autoimmune diabetes is correlated
with the level of Ins2 transcription in the mouse thymus
[6]. Breeding of Ins2−/− mice onto the NOD background
markedly accelerated insulitis and onset of diabetes [43]. In
contrast, insulitis and diabetes were considerably reduced in
Ins1−/− congenic NOD mice [44]. These observations are
explained by the dominance of Ins2 encoding proinsulin in
the murine thymus, while Ins1 encodes proinsulin in islet β
cells. In the human species, INS transcripts were measured
a tl o w e rl e v e l si nt h ef e t a lt h y m u sw i t hs h o r tc l a s sIV N T R
(variable number of tandemrepeats) alleles, a genetic trait of
T1Dsusceptibility asdiscussed above [45, 46].The contribu-
tion of thymic insulin in mediating central self-tolerance to
islet β cells was deﬁnitively demonstrated by the rapid onset
of autoimmune diabetes following thymus-speciﬁc deletion
of Ins1 and Ins2 through an elegant transgenic construction
in mice [47].
The identiﬁcation of AIRE led to further demonstration
that a thymus dysfunction plays a crucial role in the patho-
genesisoforgan-speciﬁcautoimmunediseases[48,49].Loss-
of-function AIRE single mutations are responsible for a
very rare autosomal recessive disease named autoimmune
polyendocrinopathy, candidiasis, and ectodermal dystrophy
(APECED), or autoimmune polyendocrine syndrome type 1
(APS-1). This syndrome develops in early childhood and is
characterized bymultiorgan autoimmunityand insuﬃciency
of several endocrine glands such as parathyroids, adrenal
cortex, and gonads. AIRE expression is maximal in the
thymus, mainly in mTEC, butis absent in TEC of NODmice
[50]. Depending on their genetic background, AIRE−/− mice
exhibit several signs of peripheral autoimmunity, which are
associated with a signiﬁcant decrease in thymic transcription
of neuroendocrine genes (including O t ,N p y ,I gf 2 ,and Ins2),
as well as other TSAs [9, 51, 52]. However, as shown for
GAD67,AIREdoesnotcontrol theintrathymic expression of
all TSAs. By diﬀerent aspects, AIRE-regulated transcription
in the thymus diﬀers from expression of these antigens in
eutopic tissues. For example, loss of Igf2 imprinting with
biallelic transcription has been observed in mTEC [53]. The
samestudyhasshownthatmanyTSAsinmTECareclustered
in their chromosomal location, including AIRE-dependent
and AIRE-independent gene targets [53]. Extrathymic AIRE
expression has been evidenced in secondary lymphoid
organs where AIRE also controls the expression of TSAgenes
that are diﬀerent from those regulated by AIRE in mTEC
[54]. The precise molecular mechanisms by which AIREClinical and Developmental Immunology 5
controls transcription of TSA are not completely elucidated
[55, 56]. However, it more and more appears that AIRE
uses one of its two zinc ﬁnger plant homeodomains for
binding to nonmethylated histone H3K4 and activating
gene expression, which establishes a relationship between
chromatin regulation and tissue-speciﬁc central tolerance
[57, 58]. Finally, there is mounting evidence that AIRE
is closely implicated in mTEC diﬀerentiation (reviewed in
[59]).
In collaboration with Didier Hober (Laboratory of
Virology EA3610, CHRU Lille, France), we have shown that
coxsackievirus B4 (CVB4) is capable to directly infect the
epithelial and lymphoid compartments of the human and
murine thymus and to induce a severe thymus dysfunction
with massive pre-T-cell depletion and marked upregulation
of MHC class I expression by TEC and by CD4+ CD8+
immature thymic Tcells[60,61]. Interestingly, outbred mice
can be infected with CVB4 following an oral inoculation,
which results in systemic spreading of viral RNA and a
prolonged detection of CVB4 RNA in thymus, spleen, and
blood up to 70 days postinoculation [62]. These ﬁndings
suggest that, in addition to a role for CVB4 in breaking
peripheral tolerance to islet β cells, the severe infection of
the thymus by CVB4 could enhance its virulence through
inductionofcentral tolerancetothevirus, and a still putative
breakdown in central self-tolerance to islet β cells.
5.Thymic Controlof NaturallyOccurring
CD4+CD25+TregGenerationinT1D
Naturally occurring CD4+CD25+ Treg have emerged as a
dominant T-cell population mediating peripheral tolerance.
They are potent suppressors of organ-speciﬁc autoimmunity
(T1D, inﬂammatory bowel disease, and gastritis), allograft
rejection, graft versus host disease and control immunity to
asthma and infectious agents such as parasites and viruses
[63–68]. Depletion of CD4+CD25+ Treg cells leads to the
development of various autoimmune diseases in genetically
susceptible animals. In contrast, the adoptive transfer of
CD4+CD25+ Treg in many animal models has been shown
eﬃcient in controlling organ-speciﬁc autoimmunity [69].
MultiplereportshaveimplicatedTreginT1Dprevention.
Treg depletion or interference with B7/CD28 pathway in
NOD mice has been shown to accelerate T1D onset [70, 71].
InagedNODmice,autoimmunediabetesresistancehasbeen
correlated with the expansion of CD25+ CD4+ T cells with
regulatory activity within inﬂamed pancreatic lymph nodes
[72]. Recently, Chen et al. reported that Foxp3-deﬁcient
NOD mice, which are deﬁcient in Treg, display an increased
incidence and earlier onset of T1D compared with normal
NOD mice, strongly implying a role for Treg in the control
of T1D pathogenesis [73]. Obviously, alterations in the
frequencyand/orfunctionofTregareassociated withvarious
autoimmune diseases, including T1D [74, 75]. The quantiﬁ-
cation of naturally occurring Treg is hampered by a lack of
unique surface markers. Perhaps not surprisingly, there is
some controversy in the literature regarding the frequency
of Treg in NOD mice, as determined by the identiﬁcation of
CD4+CD25 high cells in the spleen and lymphoid organs.
More importantly, however, it appears that NOD mice
harbor Treg that prevent disease development at an early
age, but lose their functional capacity later on in life, thereby
allowing pathogenic eﬀector T cells to attack pancreatic
islets [76, 77]. Similarly, the numbers of Foxp3+ Treg in
the peripheral blood of T1D patients do not appear to
be signiﬁcantly diﬀerent from healthy control subjects but
there is evidence for functional defects in their suppressive
capacity [78–80]. Therefore, there has been much interest in
the potential use of adoptive transfer of in vitro expanded
islet-speciﬁc Treg as a way of suppressing autoimmunity in
T1D patients, perhaps preserving islet-cell function in newly
diagnosed T1D.
The role of thymic self-antigens expression in the nega-
tive selection of self-reactive T cells has been well described
by others and us. Many reports have shown that thymic
mTEC and subsets of DC also play a critical role in the gen-
eration of antigen-speciﬁc CD4+CD25+Foxp3+ Treg [10].
Moreover, mTEC forming Hassall’s corpuscles in the human
thymus express thymic stromal lymphopoietin (TSLP), a
molecule that can instruct thymic and peripheral DC to
drive thymocyte CD4+CD8−CD25− diﬀerentiation into
naturally occurring regulatory CD4+CD25+T-cells [81, 82].
Importantly, Aschenbrenner et al. have shown that this
selection of Foxp3+ Treg speciﬁc for self-antigen is mediated
by AIRE+ mTEC, and the “routing” of mTEC-derived self-
antigens (i.e., direct presentation by mTEC or via transfer to
DC) may determine whether speciﬁc thymocytes are deleted
or enter the Treg lineage. Indeed, this study proposed that
mTEC-thymocyte interactions shape the Treg compartment
and dominant tolerance, whereas hematopoietic antigen-
presenting cells (mainly thymic DC) mediate recessive
deletional tolerance [11]. Taken together, these results show
that mTEC forming Hassall’s corpuscles play an important
role in central and peripheral T-cell tolerance.
6.Genetic FactorsinT1DPathogenesis
T1Disthepolygenicautoimmunedisease thathasbeenmost
intensively investigated at the genetic level. Knowledge of
geneticlocithatdeterminesusceptibilitytoT1Disimportant
foridentifyingpathogenicpathways,forimprovedprediction
of the disease and for selection of potential pharmacological
targets. The balance between susceptibility and resistance
alleles determines individual predisposition to T1D. The
most signiﬁcant part (±50%)ofgeneticsusceptibilitytoT1D
resides in the HLA class II region on chromosome 6p21, as
recognized by pioneering studies[83, 84]. The major suscep-
tibility in this region is conferred by the speciﬁc HLA class II
haplotypes DR4-DQA1∗0301-DQB1∗0302 (DQ8 molecule)
and DR3-DQA1∗0501-DQB1∗0201 (DQ2 molecule). In
contrast, the allele DQB1∗0602 (DQ6 molecule) confers
dominant protection against T1D. Theoretically, HLA class
I proteins present antigens that are processed from endoge-
nous proteins to CD8+ T cells, while HLA class II proteins
present antigens issued from exogenous proteins to CD4+
T cells. Consequently, it has long been diﬃcult to explain6 Clinical and Developmental Immunology
the relationship between insulin and T1D genetic suscepti-
bility located in the HLA class II region. This problem was
solved when very elegant crystallographic studies showed
that a dominant insulin epitope (InsB9-23) is presented
in the binding pocket of DQ8 and DQ2 proteins [85].
Since then, a comprehensive scan of the whole HLA region,
combined with potent statistical methods, has linked T1D
susceptibility to HLA class I genes HLA-B and HLA-A [86].
Other genetic linkage and association studies have iden-
tiﬁed a second locus for T1D susceptibility that corresponds
to a high polymorphic minisatellite constituted by a variable
number of tandem repeats (VNTR) [87, 88]. This VNTR
is embedded on chromosome 11p15 and controls the
transcription of the insulin (INS) and insulin-like growth
factor 2(IGF2)genesdownstream. ShortVNTRclass Ialleles
contain20–63repeatsof14-15base pairs, while intermediate
class II and long class III alleles include 64–139 and 140–210
repeats, respectively. VNTR class I alleles are associated with
TID susceptibility, whereas class III alleles confer protection.
The CTLA4 gene region on chromosome 2q33 is also
associated with susceptibility to T1D [89]. The signaling
between B7, expressed by professional antigen-presenting
cells such as DC and cytotoxic T-lymphocyte-associated
protein 4 (CTLA-4), expressed by T cells, plays a pivotal
role in peripheral T-cell tolerance. CTLA-4 is expressed
neither by thymocytes nor resting T cells, but it is detectable
after antigen-mediated T-cell activation and downregulates
responses of activated T cells. Ctla4 deletion in mice results
in an extremely severe lymphoproliferative and an autoim-
mune phenotype with lethal multiorgan tissue destruction
[90].
Another mutation in a non-HLA gene conferring sig-
niﬁcant susceptibility to T1D is a variant of the lymphoid
tyrosine phosphatase Lyp gene (PTPN22), a suppressor of
T-cell activation [91]. Lyp normally interacts with a C-
terminal Src kinase (Csk) complex to dephosphorylate pos-
itive regulatory tyrosines and downregulate signaling from
the TCR pathway. The minor allele derived from the single
nucleotide polymorphism (SNP) diﬀers in a single but
crucial amino acid residue (R620W) involved in interaction
of Lyp with Csk. Interestingly, the same variant R620W also
increases risk to other common autoimmune diseases, such
as rheumatoid arthritis, Graves’ disease, and systemic lupus
erythematosus[92]. However, the variant PTPN22620Wis a
gain-of-function mutant, since it is associated with a higher
catalyticactivity of the encoded Lyp, a marked decrease of T-
cell response to antigen stimulation, CD25 expression and
IL-10 secretion from TCR stimulation, and an increase in
peripheral memory CD4+ T cells [93, 94]. The role of this
mutationinthe pathogenesis ofT1D and other autoimmune
diseases remains to be further elucidated.
Diﬀerent studies, including a genome-wide association
analysis, have identiﬁed association of T1D with noncoding
SNPs on the chromosome 10p15 region containing CD25,
which encodes the high-aﬃnity α chain of the IL2R complex
[95]. Further mapping of the association between the IL2RA
locusand T1D supported a role ofIL2Rα in the pathogenesis
of the disease, most possibly through modulation of Treg
activity [96].
An association has also been found between T1D and
a polymorphism of the IGF2 receptor gene (IGF2R), which
seems to be subject to parental imprinting since only
maternal alleles at this polymorphism are associated with
the disease [97]. Human T1D diﬀers from other common
autoimmune disorders, which preferentially aﬀect females
(like autoimmune diabetes in the NOD mouse). Evidence
was also recently provided for an association between
T1D and polymorphisms in CYP27B1, which encodes 1α-
hydroxylase, the enzyme that transforms 25(OH) vitamin D
into bioactive 1,25(OH)2 vitamin D3 [98].
The association between T1D and viral infections has
been recently reinforced by genetic studies that have evi-
dencedalinkagebetween T1Dsusceptibilityandhostgenetic
determinants of the antiviral responses such as the antivi-
ral oligoadenylate synthetase (OAS1) and the interferon-
induced helicase (IFIH1 or MDA5), which intervenes in
innate immunity by recognition of RNA genomes of picor-
naviruses (such as coxsackie viruses) [99–101]. Therefore,
the question of a higher incidence of enterovirus infection
during childhood in countries with a high-risk of T1D de-
serves to be further investigated, particularly if one seriously
considers the possibility of anticoxsackie virus vaccination as
a potential method for T1D prevention.
7.Prospective:TheConceptof
Negative/TolerogenicSelf-Vaccination
Because of its antigen-speciﬁcity, the most attractive im-
munomodulating approach against the development of the
diabetogenic autoimmune response is the design of peptide-
based therapeutic vaccines. According to the novel knowl-
edge gained in T1D pathogenesis and the central role of a
thymus dysfunction in its development, the control of the
autoimmune process could be obtained by reprogramming
β cell tolerance through the potent tolerogenic properties
of the thymus, in particular the repertoire of thymic T1D-
related self-antigens. Contrary to insulin, the “altered self-
IGF-2,” IGF-2, and derived epitopes might be an appropriate
choice for a novel type of a negative self-vaccination that
associates competition for MHC presentation and regula-
tory responses downstream, as well as potential bystander
suppression of autoimmune responses to other T1D-related
autoantigens. This hypothesis is currently being investigated
by vaccination of NOD mice with recombinant human IGF-
2 alone or in combination with tolerogenic adjuvants.
8.Conclusion
The thymus plays a central role in the establishment of
central immunological self-tolerance towards Langerhans’
insulin-secreting islet β cells, and there is now evidence that
T1D development results from a breakdown of thymus-
dependent tolerance to insulin family-derived epitopes.
This knowledge should translate in the very near future
to the design of novel tolerogenic/regulatory approaches
aimed at restoring the immunological tolerance speciﬁc of
islet β cells, which represents an appealing strategy for bothClinical and Developmental Immunology 7
prevention and cure of T1D, one of the heaviest prices paid
by the human species for having evolved the advantage of
the extreme diversity and eﬃciency of adaptive immune
responses against new biological threats.
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